Summary by Moomoo AI
AND PLATINUM PHARMACEUTICAL-B (02142) ANNOUNCED THAT ITS DEVELOPED BI-SPECIFIC ANTIBODY HBM9027 HAS RECEIVED A NEW DRUG RESEARCH APPLICATION (IND) LICENSE FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND WILL LAUNCH ITS FIRST HUMAN BODY (FIH) CLINICAL TRIAL IN THE UNITED STATES. The Phase I trial was designed to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of HBM9027 in patients with late-stage solid tumors. Developed on the all-human HBICE® platform, based on and proprietary to platinum medicine, HBM9027 is a novel PD-L1xCD40 dual-specific antibody designed to activate PD-L1-dependent CD40 and demonstrated good safety and strong antitumor effects in preclinical studies. The Company reminds potential investors to exercise caution when buying and selling shares and cautions that HBM9027 cannot guarantee successful development or eventual sale. This announcement was made by Dr. Wang Jinsong, Chairman and Executive Director of the Company, on 24 January 2024.